Review
Copyright ©The Author(s) 2024.
World J Gastroenterol. Oct 28, 2024; 30(40): 4339-4353
Published online Oct 28, 2024. doi: 10.3748/wjg.v30.i40.4339
Table 1 Key pathophysiological pathways in type 1, type 2, and type 3 diabetes
Pathway
Type 1 diabetes
Type 2 diabetes
Type 3 diabetes (Alzheimer’s disease)
Insulin productionAutoimmune destruction of pancreatic beta cells leads to absolute insulin deficiencyInsulin resistance in peripheral tissues leads to compensatory hyperinsulinemia, followed by beta-cell dysfunction and relative insulin deficiencyInsulin resistance and deficiency in the brain contribute to impaired glucose metabolism and cognitive decline
Immune system involvementAutoimmune response targeting beta cells, involving T cell-mediated destructionChronic low-grade inflammation contributes to insulin resistance and beta-cell dysfunctionPossible involvement of neuroinflammation and immune dysregulation contributing to neurodegeneration
Glucose metabolismHyperglycemia due to lack of insulin, resulting in impaired glucose uptake by cellsHyperglycemia due to insulin resistance and inadequate compensatory insulin secretion by beta cellsImpaired glucose metabolism in the brain leads to reduced energy supply and cognitive impairment
Beta-cell functionProgressive loss of beta-cell mass due to autoimmune attackGradual decline in beta-cell function due to chronic insulin resistance, oxidative stress, and inflammationNot directly related to beta cells, but brain insulin signaling impairment is a key factor
Associated complicationsKetoacidosis, retinopathy, nephropathy, neuropathy, cardiovascular diseaseRetinopathy, nephropathy, neuropathy, cardiovascular disease, non-alcoholic fatty liver diseaseCognitive decline, memory loss, dementia, potential overlap with Alzheimer’s disease
Therapeutic targetsInsulin replacement therapy, immunomodulation, beta-cell regenerationInsulin sensitizers, lifestyle modifications, beta-cell support and regeneration, and anti-inflammatory agentsImproving brain insulin sensitivity, neuroprotective agents, and management of cognitive decline